Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Lopez, Salvatore; Schwab, Carlton L; Cocco, Emiliano; Bellone, Stefania; Bonazzoli, Elena; English, Diana P; Schwartz, Peter E; Rutherford, Thomas; Angioli, Roberto; Santin, Alessandro D

Lopez, Salvatore; Schwab, Carlton L; Cocco, Emiliano; Bellone, Stefania; Bonazzoli, Elena; English, Diana P; Schwartz, Peter E; Rutherford, Thomas; Angioli, Roberto; Santin, Alessandro D.

Afiliación

Lopez S; Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Via Alvaro del Portillo 21, 00144 Roma, Italy.
Schwab CL; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
Cocco E; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
Bellone S; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
Bonazzoli E; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
English DP; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
Schwartz PE; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
Rutherford T; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA.
Angioli R; Division of Gynecologic Oncology, University Campus Bio-Medico of Roma, Via Alvaro del Portillo 21, 00144 Roma, Italy.
Santin AD; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA. Electronic address: alessandro.santin@yale.edu.

Gynecol Oncol ; 135(2): 312-7, 2014 Nov.

Article en En | MEDLINE | ID: mdl-25172762

Asunto(s)

Antineoplásicos/farmacología; Carcinoma/genética; Puntos de Control del Ciclo Celular/efectos de los fármacos; Proliferación Celular/efectos de los fármacos; Imidazoles/farmacología; Neoplasias Quísticas, Mucinosas y Serosas/genética; Oxazepinas/farmacología; Fosfatidilinositol 3-Quinasas/genética; Receptor ErbB-2/genética; Neoplasias Uterinas/genética; Adulto; Anciano; Anciano de 80 o más Años; Animales; Línea Celular Tumoral; Fosfatidilinositol 3-Quinasa Clase I; Ensayos de Selección de Medicamentos Antitumorales; Femenino; Amplificación de Genes; Humanos; Hibridación Fluorescente in Situ; Técnicas In Vitro; Ratones; Persona de Mediana Edad; Inhibidores de las Quinasa Fosfoinosítidos-3; Ensayos Antitumor por Modelo de Xenoinjerto

Palabras clave

GDC-0032; HER2/neu; PIK3CA mutation; PIK3CA-mutant mouse; Taselisib; Uterine serous tumors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oxazepinas / Neoplasias Uterinas / Carcinoma / Neoplasias Quísticas, Mucinosas y Serosas / Receptor ErbB-2 / Fosfatidilinositol 3-Quinasas / Proliferación Celular / Puntos de Control del Ciclo Celular / Imidazoles / Antineoplásicos Límite: Adult / Aged / Aged80 / Animals / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2014 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google